TP53 and non-small cell lung carcinoma: Collectively, this study provides a novel perspective for the stratification of immunotherapy via mutational profiling in patients with NSCLC and suggests that TP53 mutation status, as well as the biopsy lesion type, determines the difference in immunotherapy predictors.